Abuse-Deterrent Pharmaceutical Composition with Aversion Properties
AssigneeAardvark Therapeutics Inc.
InventorsJane Wu LEE, Tien-Li LEE
Life of this patent
Estimating the term…
Loading patent…
AssigneeAardvark Therapeutics Inc.
InventorsJane Wu LEE, Tien-Li LEE
Estimating the term…
There is disclosed an improved abuse-deterrent pharmaceutical composition comprising a controlled pharmaceutical substance in a formulation comprising at least two gel-forming excipients selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose, and a bitter-agonist compound selected from the group consisting of denatonium salts (including denatonium acetate (DA), denatonium benzoate (DB), denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate) chlorpheniramine, diphenidol, famotidine, haloperidol, quinine, parthenolide, and aristolochic acid. Preferably, the controlled pharmaceutical substance is an amphetamine or a pharmaceutically acceptable salt thereof. Preferably, the bitter receptor agonist is a denatonium salt selected from DA, DB, denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate provided at from about 0.5 mg per dose administered to about 10 mg per dose administered. There is further disclosed a use for denatonium acetate (DA) as a pharmaceutical grade aversive agent to be added to abuse-deterrent formulations to deter snorting or smoking a controlled pharmaceutical substance at a dose of about 0.5 mg to about 10 mg per dose.
An abuse-deterrent pharmaceutical composition comprising a controlled pharmaceutical substance selected from the group consisting of amphetamine, dextroamphetamine, metylphenidate, amobarbital, secobarbital, butalbital/acetomenophen or aspirin/caffeine, dydrocodone, oxycodone, oxymorphone, morphine, codeine, fentanyl, alprazolam, chlordiazepoxide, clonazepam, clorazepate, diazepam, estazolam, flurazepam, lorazepam, zolpidem, zaleplon, and eszopiclone, in a formulation comprising at least two gel-forming excipients selected from the group consisting of PEG ester, poloxamer, water-soluble anionic polysaccharide, and carboxymethylcellulose, and a bitter-agonist compound selected from the group consisting of denatonium salts, denatonium acetate (DA), denatonium benzoate (DB), denatonium chloride, denatonium citrate, denatonium maleate, denatonium saccharide, and denatonium tartrate, chlorpheniramine, diphenidol, famotidine, haloperidol, quinine, parthenolide, and aristolochic acid.
Dependencies are inferred from the claim text.